Connection

Michael Gold to Cardiac Resynchronization Therapy

Back to Details
This is a "connection" page, showing publications Michael Gold has written about Cardiac Resynchronization Therapy.
Michael Gold
Connection Strength
23.731
Cardiac Resynchronization Therapy
  1. Association of left ventricular remodeling with cardiac resynchronization therapy outcomes. Heart Rhythm. 2023 02; 20(2):173-180.
    View in: PubMed
    Score: 0.701
  2. Association of interventricular activation delay with clinical outcomes in cardiac resynchronization therapy. Heart Rhythm. 2023 Mar; 20(3):385-392.
    View in: PubMed
    Score: 0.701
  3. Role of Electrical Delay in Cardiac Resynchronization Therapy Response. Card Electrophysiol Clin. 2022 06; 14(2):233-241.
    View in: PubMed
    Score: 0.678
  4. CRT Efficacy in "Mid-Range" QRS Duration Among Asians Contrasted to Non-Asians, and Influence of Height. JACC Clin Electrophysiol. 2022 02; 8(2):211-221.
    View in: PubMed
    Score: 0.654
  5. The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. Europace. 2021 10 09; 23(10):1586-1595.
    View in: PubMed
    Score: 0.648
  6. Electrical delays in quadripolar leads with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2021 09; 32(9):2498-2503.
    View in: PubMed
    Score: 0.638
  7. Redefining the Classifications of Response to Cardiac Resynchronization Therapy: Results From the REVERSE Study. JACC Clin Electrophysiol. 2021 07; 7(7):871-880.
    View in: PubMed
    Score: 0.621
  8. The ECG Belt for CRT response trial: Design and clinical protocol. Pacing Clin Electrophysiol. 2020 10; 43(10):1063-1071.
    View in: PubMed
    Score: 0.600
  9. Left Bundle Branch Pacing: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 12 17; 74(24):3039-3049.
    View in: PubMed
    Score: 0.571
  10. Comparison of measures of ventricular delay on cardiac resynchronization therapy response. Heart Rhythm. 2020 04; 17(4):615-620.
    View in: PubMed
    Score: 0.569
  11. The effect of posture, exercise, and atrial pacing on atrioventricular conduction in systolic heart failure. J Cardiovasc Electrophysiol. 2019 12; 30(12):2892-2899.
    View in: PubMed
    Score: 0.568
  12. Optimization of Cardiac Resynchronization Therapy: Should Perioperative Hemodynamic Measurements Be Routine? JACC Clin Electrophysiol. 2019 09; 5(9):1026-1027.
    View in: PubMed
    Score: 0.560
  13. Electrocardiogram in Cardiac?Resynchronization Therapy: Is Non-Left Bundle Branch Block an Oversimplification? J Am Coll Cardiol. 2019 06 25; 73(24):3100-3101.
    View in: PubMed
    Score: 0.553
  14. The rationale and design of the SMART CRT trial. Pacing Clin Electrophysiol. 2018 09; 41(9):1212-1216.
    View in: PubMed
    Score: 0.521
  15. Effect of Interventricular Electrical Delay on Atrioventricular Optimization for Cardiac Resynchronization Therapy. Circ Arrhythm Electrophysiol. 2018 08; 11(8):e006055.
    View in: PubMed
    Score: 0.520
  16. Predicting cardiac resynchronization therapy outcomes: It is more than just left bundle branch block. Heart Rhythm. 2018 11; 15(11):1673-1674.
    View in: PubMed
    Score: 0.514
  17. Acute biventricular hemodynamic effects of cardiac resynchronization therapy in right bundle branch block. Heart Rhythm. 2018 10; 15(10):1525-1532.
    View in: PubMed
    Score: 0.513
  18. Computer Modeling: The Future of Cardiac Resynchronization Therapy Patient Selection? Circ Arrhythm Electrophysiol. 2018 01; 11(1):e006104.
    View in: PubMed
    Score: 0.499
  19. The role of interventricular conduction delay to predict clinical response with cardiac resynchronization therapy. Heart Rhythm. 2017 12; 14(12):1748-1755.
    View in: PubMed
    Score: 0.496
  20. Impact of Renal Function on Survival After Cardiac Resynchronization Therapy. Am J Cardiol. 2017 Jul 15; 120(2):262-266.
    View in: PubMed
    Score: 0.476
  21. The Impact of the PR Interval in Patients?Receiving Cardiac Resynchronization Therapy: Results From the REVERSE Study. JACC Clin Electrophysiol. 2017 08; 3(8):818-826.
    View in: PubMed
    Score: 0.476
  22. Economic Value and Cost-Effectiveness of?Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. JACC Heart Fail. 2017 03; 5(3):204-212.
    View in: PubMed
    Score: 0.467
  23. The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Heart Fail Clin. 2017 Jan; 13(1):209-223.
    View in: PubMed
    Score: 0.466
  24. The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2016 Aug; 39(8):863-9.
    View in: PubMed
    Score: 0.448
  25. The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Card Electrophysiol Clin. 2015 Dec; 7(4):765-79.
    View in: PubMed
    Score: 0.432
  26. Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study. JACC Heart Fail. 2015 Sep; 3(9):691-700.
    View in: PubMed
    Score: 0.423
  27. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015 Mar; 12(3):524-530.
    View in: PubMed
    Score: 0.402
  28. Newer Indications for ICD and CRT. Cardiol Clin. 2014 May; 32(2):181-90.
    View in: PubMed
    Score: 0.382
  29. The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2014 Jun; 25(6):624-30.
    View in: PubMed
    Score: 0.381
  30. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1163-8.
    View in: PubMed
    Score: 0.373
  31. The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm. 2013 Jul; 10(7):988-93.
    View in: PubMed
    Score: 0.358
  32. Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial. J Cardiovasc Electrophysiol. 2012 Dec; 23(12):1317-25.
    View in: PubMed
    Score: 0.342
  33. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012 Aug 14; 126(7):822-9.
    View in: PubMed
    Score: 0.341
  34. Subcutaneous implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2012 Jun 01; 5(3):587-93.
    View in: PubMed
    Score: 0.339
  35. Optimization of cardiac resynchronization therapy: importance of programmed parameters. J Cardiovasc Electrophysiol. 2012 Jan; 23(1):110-8.
    View in: PubMed
    Score: 0.329
  36. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011 Oct; 32(20):2516-24.
    View in: PubMed
    Score: 0.322
  37. Cardiac resynchronization therapy for mild heart failure: the time has come. Circulation. 2011 Jan 18; 123(2):195-202.
    View in: PubMed
    Score: 0.308
  38. A prospective, randomized comparison of the acute hemodynamic effects of biventricular and left ventricular pacing with cardiac resynchronization therapy. Heart Rhythm. 2011 May; 8(5):685-91.
    View in: PubMed
    Score: 0.307
  39. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm. 2011 May; 8(5):679-84.
    View in: PubMed
    Score: 0.307
  40. Cardiac resynchronization therapy in mild heart failure: a review of the REVERSE and MADIT-CRT trials. Curr Cardiol Rep. 2010 Sep; 12(5):367-73.
    View in: PubMed
    Score: 0.300
  41. Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials. Circulation. 2023 Mar 07; 147(10):812-823.
    View in: PubMed
    Score: 0.177
  42. Long-term outcomes in nonprogressors to cardiac resynchronization therapy. Heart Rhythm. 2023 02; 20(2):165-170.
    View in: PubMed
    Score: 0.175
  43. Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol. 2022 09 27; 80(13):1205-1216.
    View in: PubMed
    Score: 0.173
  44. European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. Europace. 2022 01 04; 24(1):165-172.
    View in: PubMed
    Score: 0.165
  45. The importance of early evaluation after cardiac resynchronization therapy to redefine response: Pooled individual patient analysis from 5 prospective studies. Heart Rhythm. 2022 04; 19(4):595-603.
    View in: PubMed
    Score: 0.164
  46. Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. J Am Heart Assoc. 2021 03 16; 10(6):e018127.
    View in: PubMed
    Score: 0.155
  47. Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial. Am Heart J. 2021 05; 235:158-162.
    View in: PubMed
    Score: 0.155
  48. Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial. J Med Econ. 2020 Dec; 23(12):1401-1408.
    View in: PubMed
    Score: 0.152
  49. Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. ESC Heart Fail. 2020 10; 7(5):2972-2982.
    View in: PubMed
    Score: 0.150
  50. Future research prioritization in cardiac resynchronization therapy. Am Heart J. 2020 05; 223:48-58.
    View in: PubMed
    Score: 0.145
  51. Evaluation, Management, and Outcomes of Patients Poorly Responsive to Cardiac?Resynchronization Device Therapy. J Am Coll Cardiol. 2019 11 26; 74(21):2588-2603.
    View in: PubMed
    Score: 0.142
  52. Plasticity of left ventricular function with cardiac resynchronization therapy. J Interv Card Electrophysiol. 2020 Mar; 57(2):289-294.
    View in: PubMed
    Score: 0.138
  53. Design and rationale for the Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in non-responders and previously untreatable patients (SOLVE-CRT) trial. Am Heart J. 2019 11; 217:13-22.
    View in: PubMed
    Score: 0.136
  54. Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
    View in: PubMed
    Score: 0.133
  55. 2018 ACC/AHA/HRS guideline on the?evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Heart Rhythm. 2019 09; 16(9):e227-e279.
    View in: PubMed
    Score: 0.132
  56. 2018 ACC/AHA/HRS guideline on the?evaluation and management of?patients with bradycardia and cardiac?conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2019 09; 16(9):e128-e226.
    View in: PubMed
    Score: 0.132
  57. The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail. 2018 04; 20(4):780-791.
    View in: PubMed
    Score: 0.125
  58. Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.123
  59. Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing. Eur J Heart Fail. 2017 07; 19(7):950-957.
    View in: PubMed
    Score: 0.121
  60. Predictors of short-term clinical response to cardiac resynchronization therapy. Eur J Heart Fail. 2017 08; 19(8):1056-1063.
    View in: PubMed
    Score: 0.118
  61. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac?Resynchronization: Results From the REVERSE Trial. JACC Heart Fail. 2017 03; 5(3):169-178.
    View in: PubMed
    Score: 0.118
  62. Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy). Circ Arrhythm Electrophysiol. 2016 11; 9(11).
    View in: PubMed
    Score: 0.115
  63. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). J Am Heart Assoc. 2015 Sep 11; 4(9):e002054.
    View in: PubMed
    Score: 0.106
  64. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur Heart J. 2015 Nov 01; 36(41):2780-9.
    View in: PubMed
    Score: 0.106
  65. Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. Heart Rhythm. 2015 Dec; 12(12):2402-10.
    View in: PubMed
    Score: 0.106
  66. The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. J Card Fail. 2015 Jul; 21(7):601-7.
    View in: PubMed
    Score: 0.103
  67. Long-term effectiveness of the combined minute ventilation and patient activity sensors as predictor of heart failure events in patients treated with cardiac resynchronization therapy: Results of the Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT device Trial (CLEPSYDRA) study. Eur J Heart Fail. 2014 Jun; 16(6):663-70.
    View in: PubMed
    Score: 0.096
  68. Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure. Circ Heart Fail. 2013 Nov; 6(6):1180-9.
    View in: PubMed
    Score: 0.092
  69. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
    View in: PubMed
    Score: 0.092
  70. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013 Sep; 34(33):2592-9.
    View in: PubMed
    Score: 0.090
  71. Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail. 2012 Dec; 14(12):1420-8.
    View in: PubMed
    Score: 0.086
  72. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 2012 Sep; 14(9):1236-86.
    View in: PubMed
    Score: 0.086
  73. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm. 2012 Sep; 9(9):1524-76.
    View in: PubMed
    Score: 0.086
  74. Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm. 2012 May; 9(5):736-41.
    View in: PubMed
    Score: 0.082
  75. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15; 123(10):1061-72.
    View in: PubMed
    Score: 0.078
  76. Temporal stability of defibrillation thresholds with cardiac resynchronization therapy. Heart Rhythm. 2011 Jul; 8(7):1008-13.
    View in: PubMed
    Score: 0.077
  77. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010 Nov 23; 56(22):1826-31.
    View in: PubMed
    Score: 0.076
  78. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
    View in: PubMed
    Score: 0.076
  79. Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). J Card Fail. 2015 Jun; 21(6):479-88.
    View in: PubMed
    Score: 0.026
  80. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J. 2012 Nov; 33(21):2662-71.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.